VHT is the Vanguard Health Care ETF, a fund that tracks the MSCI U.S. Investable Market Health Care 25/50 Index, holding about 405 U.S. healthcare companies spanning pharmaceuticals, biotechnology, medical devices, and health insurers. As an ETF, it does not receive standalone analyst price targets the way an individual stock does. The $360 figure used here is a fallback objective drawn from public discussion and technical context: it sits roughly 10% above the fund's recent price, just beyond its all-time high, and aligns with the upper end of publicly discussed healthcare outlooks. It should not be read as a published consensus.
For perspective, TipRanks computes a holdings-weighted 12-month forecast of about $339.45 based on analyst targets across 424 stocks held in the fund, with a range from roughly $276 to $407. A separate view from financial media citing Wall Street estimates has pointed to a roughly 21% total return for the healthcare sector over the coming year. The $360 milestone therefore represents a reasonable, publicly grounded level—not a guarantee.
VHT recently changed hands around $327, near the top of its 52-week range of approximately $265 to $332. Reaching $360 would require a gain of about 10%, which is best described as a modest move for a diversified sector fund. Notably, the fund has already recovered sharply from its 52-week low, so the path to $360 would require breaking decisively to a new all-time high and then sustaining that momentum.
The realistic route would depend on continued earnings growth from mega-cap holdings such as Eli Lilly (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK), and UnitedHealth Group (UNH), which together represent a meaningful share of the portfolio. A rotation back into defensive, dividend-paying sectors would also help, as would multiple expansion if interest rates ease.
VHT's most important structural level is its all-time high near $331–$332, which also acts as near-term resistance. A decisive breakout above that zone would put the fund in uncharted territory and make the $360 psychological level the next natural milestone to watch. On the downside, support sits near the recent consolidation zone around $310–$315, with the 52-week low near $265 serving as the broader floor. The fund's long-term trend remains upward, having rebounded strongly from its 52-week low.
Holdings-weighted analyst targets typically reflect a roughly 12-month research horizon, though individual estimates vary widely. Investors tracking the path toward $360 should watch quarterly earnings from the fund's largest holdings, any guidance revisions across pharma and managed care, Federal Reserve rate decisions, and changes in healthcare policy. For an ETF, fund flows and rebalancing of the underlying index can also influence performance over time.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For an index fund like VHT, such tools can help traders spot shifting trends in sector momentum, identify entry and exit zones, and monitor positions more efficiently than manual scanning allows. Investors seeking a data-driven complement to their own research can use these signals to stay ahead of changing market structure.
The $360 objective for VHT is a publicly grounded, technically informed milestone rather than an analyst consensus. It implies a roughly 10% advance from the fund's recent price near $327—a modest move that would require a decisive breakout to a new all-time high. Support could come from defensive demand, a reacceleration in sector earnings, and falling interest rates, while the patent cliff, elevated valuations, and policy risk are the principal obstacles. The wide spread between the holdings-weighted analyst range near $276 and $407 underscores genuine disagreement about the sector's outlook. Investors should monitor mega-cap earnings, rate policy, and fund flows rather than treat any single level as a foregone conclusion.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, VHT has been closely correlated with FHLC. These tickers have moved in lockstep 100% of the time. This A.I.-generated data suggests there is a high statistical probability that if VHT jumps, then FHLC could also see price increases.
| Ticker / NAME | Correlation To VHT | 1D Price Change % | ||
|---|---|---|---|---|
| VHT | 100% | +0.20% | ||
| FHLC - VHT | 100% Closely correlated | +0.18% | ||
| IYH - VHT | 99% Closely correlated | +0.11% | ||
| XLV - VHT | 99% Closely correlated | +0.29% | ||
| IXJ - VHT | 97% Closely correlated | +0.01% | ||
| RSPH - VHT | 89% Closely correlated | -0.31% | ||
More | ||||